## TEMPORARY REMOVAL: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Qingxian Cai<sup>a,1</sup>, Minghui Yang<sup>a,1</sup>, Dongjing Liu<sup>a,1</sup>, Jun Chen<sup>a,1</sup>, Dan Shu<sup>a</sup> Junxia Xia<sup>a</sup>, Xuejiao Liao<sup>a</sup>, Yuanbo Gu<sup>a</sup>, Qiue Cai<sup>a</sup>, Yang Yang<sup>a</sup>, Chenguang Shen<sup>a</sup> Xiaohe Li<sup>a</sup>, Ling Peng<sup>a</sup>, Deliang Huang<sup>a</sup>, Jing Zhang<sup>a</sup>, Shurong Zhang<sup>a</sup> Fuxiang Wang<sup>a</sup>, Jiaye Liu<sup>a</sup>, Li Chen<sup>a</sup>, Shuyan Chen<sup>a</sup>, Zhaoqin Wang<sup>a</sup> Zheng Zhang<sup>a</sup>, Ruiyuan Cao<sup>a</sup>, Wu Zhong<sup>b,\*</sup>, Yingxia Liu<sup>a,\*</sup>, Lei Liu<sup>a,\*</sup>

<sup>a</sup> National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518100, China

[Error ce:source-text]

National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518100, China

<sup>b</sup> National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China

[Error ce:source-text] National

Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China

**Error** /ce:source-text]

The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated.

<sup>\*</sup> Corresponding authors.

E-mail addresses: zhongwu@bmi.ac.cn (W. Zhong), yingxialiu@hotmail.com (Y. Liu), liulei3322@aliyun.com (L. Liu).

<sup>&</sup>lt;sup>1</sup> These authors contributed equally to this work.